The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

The FDA has recently approved AstraZeneca’s Imfinzi (durvalumab) for perioperative use in cisplatin-eligible muscle-invasive bladder cancer (MIBC), based on the Phase III NIAGARA trial. With its ...

Durvalumab with chemotherapy was approved as the first perioperative immunotherapy for muscle-invasive bladder cancer, reducing disease progression risk. From Crohn disease to uncomplicated ...

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, ...

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer ...

Q1 2025 Earnings Call Transcript May 1, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $4.9, expectations were $4.27. Operator: My name is Julianne and I’ll be your conference ...

A study in Nature Communications found that older cancer patients have similar outcomes with immune checkpoint inhibitors as ...

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder ...